Immunovant, Inc. (IMVT): Price and Financial Metrics

Immunovant, Inc. (IMVT): $29.35

1.37 (-4.46%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add IMVT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#241 of 360

in industry

IMVT Price/Volume Stats

Current price $29.35 52-week high $45.58
Prev. close $30.72 52-week low $14.11
Day low $28.79 Volume 1,484,300
Day high $30.52 Avg. volume 1,232,834
50-day MA $33.70 Dividend yield N/A
200-day MA $31.66 Market Cap 4.26B

IMVT Stock Price Chart Interactive Chart >


Immunovant, Inc. (IMVT) Company Bio


Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.


IMVT Latest News Stream


Event/Time News Detail
Loading, please wait...

IMVT Latest Social Stream


Loading social stream, please wait...

View Full IMVT Social Stream

Latest IMVT News From Around the Web

Below are the latest news stories about IMMUNOVANT INC that investors may wish to consider to help them evaluate IMVT as an investment opportunity.

Immunovant (IMVT) Rose on Positive Clinical Trial

Chartwell Investment Partners, LLC, an affiliate of Carillon Tower Advisers, Inc., released the “Carillon Chartwell Small Cap Value Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. Information technology and industrials were the top-performing sectors in the Carillon Chartwell Small Cap Growth Fund, with alpha production coming from well-chosen stocks. […]

Yahoo | December 26, 2023

Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off

Immunovant unveiled promising results for a Graves' disease treatment on Thursday, helping IMVT stock reverse a recent downfall.

Yahoo | December 21, 2023

Immunovant (IMVT) Up on Upbeat Initial Batoclimab GD Study Data

Immunovant (IMVT) announces positive initial data from the mid-stage study of batoclimab in patients with Graves' disease. The stock gains 12% in the after-market hours, following the news.

Yahoo | December 21, 2023

Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%

Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in patients with Graves' disease. Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism). The company says the results show that batoclimab meaningfully exceeded 50% response rates. Consistent with studies of batoclimab in other indications, 680 mg administered subcutaneously (SC) in t

Yahoo | December 21, 2023

Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves’ disease meaningfully exceeded 50% response rates. This Phase 2 proof-of-concept trial is an open-label study to assess the safety and efficacy of batoclimab in Graves

Yahoo | December 20, 2023

Read More 'IMVT' Stories Here

IMVT Price Returns

1-mo -4.40%
3-mo -30.71%
6-mo -22.25%
1-year 105.68%
3-year 84.42%
5-year N/A
YTD -30.33%
2023 137.35%
2022 108.33%
2021 -81.55%
2020 191.05%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!